Radical Hypofractionated Radiotherapy for Localized Prostate Cancer

Inclusion Criteria: * Age: ≥18 years old; * European Cooperative Oncology Group score(ECOG):≤ 2; * Patients with pathologically diagnosed prostate cancer; * Clinical stage was cTanyN0M0 any Gleason / ISUP group; * Expected survival time \>5 years; * The patient has no contraindications to radiotherapy and is suitable and willing to undergo radiotherapy; * Patients who voluntarily accept the experimental study protocol after being informed about the existing treatment options; Exclusion Criteria: * Patients who have received any other early treatment for prostate cancer, including radiotherapy, chemotherapy, focal therapy, etc; * a previous history of pelvic and abdominal radiotherapy; * Prior hormonal therapy (castration or antiandrogen); * Patients with other malignancies and acute or chronic infections such as human immunodeficiency virus (HIV) (+), hepatitis C virus (HCV) (+) and/or positive syphilis; * Patients that the investigator considers unsuitable to participate in the clinical trial; patients with other serious systemic diseases, evaluation and compliance of the trial, including severe respiratory, circulatory, neurological, mental, digestive, endocrine, immune, urinary, and other systemic diseases; * Patients with contraindications related to radiotherapy; * Participate in other clinical trials that are mutually exclusive with the study intervention within 4 weeks prior to the start of the study; * Patients unable to provide written informed consent or demonstrate poor treatment compliance